Savara reports first quarter 2024 financial results and provides business update

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending march 31, 2024 and provided a business update. “the impala-2 trial remains on-track and we look forward to reporting top line results by the end of the second quarter,” said matt pauls, chair and ceo, savara. “following that, and assuming positive data, we expect to file a bla in the fi.
SVRA Ratings Summary
SVRA Quant Ranking